---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-026931"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-09-09T23:59:59+00:00"
generated_at: "2026-05-17T07:23:01.803993+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Telomir reports preclinical data: Telomir-1 reactivates CDKN2A, beats rapamycin and chemo

## Summary
- New data in PC3 human prostate cancer xenografts shows Telomir-1 inhibits DNA hypermethylation of CDKN2A.
- Telomir-1 outperformed rapamycin and chemotherapy in reactivating the master tumor suppressor CDKN2A.
- Findings build on prior STAT1 data, supporting Telomir-1 as a broad-spectrum DNA methylation reset therapy.
- Company advancing pre-IND program with CMC and IND-enabling studies toward first IND submission.

## SEC filing metadata
- accession: 0001641172-25-026931
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000164117225026931/0001641172-25-026931-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000164117225026931/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-026931
- JSON: https://secwatch.observer/filing/0001641172-25-026931.json
- Plain text: https://secwatch.observer/filing/0001641172-25-026931.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.